NCT04250597View on ClinicalTrials.gov

Study of GNX102 in Patients With Advanced Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

July 29, 2020

Primary Completion Date

July 26, 2023

Study Completion Date

July 26, 2023

Conditions
Solid TumorMetastatic CancerAdvanced CancerUnresectable Solid Neoplasm
Interventions
DRUG

GNX102

Dose Escalation

DRUG

GNX102

Expansion Phase

Trial Locations (8)

19111

Fox Chase Cancer Center, Philadelphia

53226

Froedtert Hospital & the Medical College of Wisconsin, Milwaukee

55303

Regions Cancer Care Center, Saint Paul

90033

USC Norris Comprehensive Cancer Center, Los Angeles

92663

Hoag Cancer Center (USC), Newport Beach

97213

Providence Cancer Institute Earle A. Chiles Research Institute, Portland

404332

China Medical University Hospital (CMUH), Taichung

704302

National Cheng Kung University Hospital (NCKUH), Tainan City

Sponsors

Lead Sponsor

GlycoNex, Inc.
All Listed Sponsors
lead

GlycoNex, Inc.

INDUSTRY